Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...

Gilead Sciences (NASDAQ:GILD) underwent analysis by 11 analysts in the last ... with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $77.91, along ...

--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq ... to sharing new research that highlights the breadth of our antiviral portfolio and expanding pipeline as we strive to treat, prevent, cure ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

“We look forward to sharing new research that highlights the breadth of our antiviral portfolio and expanding ... Virology Therapeutic Area Head at Gilead Sciences. “The data reflect our ...

“We look forward to sharing new research that highlights the breadth of our antiviral portfolio and expanding pipeline as ... Virology Therapeutic Area Head at Gilead Sciences. “The data reflect our ...

Gilead Sciences is known for its portfolio of treatments in areas such ... providing a more comprehensive analysis of the company's financial position and market performance.

Gilead's ongoing commitment to antiviral innovation is evident in its extensive portfolio ... in a deeper analysis, InvestingPro offers 11 additional tips for Gilead Sciences, providing a more ...